11. The method of claim 10 wherein said modulating is inhibiting.

12. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating a disease in a patient, wherein said disease is associated with JAK activity~~, comprising administering to said patient a therapeutically effective amount of a salt of any one of claims 1 to 5~~.

13. The ~~method~~ use of claim 12 wherein said disease is allograft rejection or graft versus host disease.

14. The ~~method~~ use of claim 12 wherein said disease is an autoimmune disease.

15. The ~~method~~ use of claim 14 wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder.

16. The ~~method~~ use of claim 12 wherein said autoimmune disease is bullous skin disorder.

17. The ~~method~~ use of claim 16 wherein said bullous skin disorder is pemphigus vulgaris (PV) or bullous pemphigoid (BP).

18. The ~~method~~ use of claim 12 wherein said disease is a skin disorder.

19. The ~~method~~ use of claim 18 wherein said skin disorder is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.

20. The ~~method~~ use of claim 12 wherein said disease is a viral disease.

21. The ~~method~~ use of claim 20 wherein said viral disease is Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV) or Human Papilloma Virus (HPV).

22. The ~~method~~ use of claim 12 wherein said disease is cancer.

23. The ~~method~~ use of claim 22 wherein said cancer is a solid tumor

24. The ~~method~~ use of claim 22 wherein said cancer is prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease or pancreatic cancer.

25. The ~~method~~ use of claim 24 wherein said cancer is prostate cancer.

26. The ~~method~~ use of claim 22 wherein said cancer is hematological.

27. The ~~method~~ use of claim 26 wherein said cancer is lymphoma, leukemia, or multiple myeloma.

28. The ~~method~~ use of claim 22 wherein said cancer is a skin cancer.

29. The ~~method~~ use of claim 28 wherein said skin cancer is cutaneous T-cell lymphoma or cutaneous B-cell lymphoma.

30. The ~~method~~ use of claim 22 wherein said cancer is multiple myeloma.

31. The ~~method~~ use of claim 12 wherein said disease is characterized by a mutant JAK2.

32. The ~~method~~ use of claim 31 wherein at least one mutation of said mutant JAK2 resides in the pseudo-kinase domain of said JAK2.

33. The ~~method~~ use of claim 12 wherein said disease is a myeloproliferative disorder.

34. The ~~method~~ use of claim 33 wherein said myeloproliferative disorder (MPD) is polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), or systemic mast cell disease (SMCD).

35. The ~~method~~ use of claim 12 wherein said disease is an inflammatory disease.

36. The ~~method~~ use of claim 35 wherein said disease is an inflammatory disease of the eye.

37. The ~~method~~ use of claim 36 wherein said disease is iritis, uveitis, scleritis, or conjunctivitis.

38. The ~~method~~ use of claim 35 wherein said disease is an inflammatory disease of the respiratory tract.

39. The ~~method~~ use of claim 35 wherein said inflammatory disease concerns the upper respiratory tract.

40. The ~~method~~ use of claim 35 wherein said inflammatory disease concerns the lower respiratory tract.

41. The ~~method~~use of claim 35 wherein said inflammatory disease is an inflammatory myopathy.

42. The ~~method~~ use of claim 35 wherein said inflammatory disease is myocarditis.

43. The ~~method~~ use of claim 12 wherein said disease is ischemia reperfusion or related to an ischemic event.

44. The ~~method~~ use of claim 12 wherein said disease is anorexia or cachexia resulting from or associated with cancer.

45. The ~~method~~ use of claim 12 wherein said disease is fatigue resulting from or associated with cancer.

46. Use of a salt of any one of claims 1 to 5 in the preparation on a medicament for ~~A method of~~ treating cancer in a patient~~, comprising administering to said patient a therapeutically effective amount of a salt of any one of claims 1 to 5~~.

47. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating a skin disorder in a patient ~~comprising topically administering to said patient a therapeutically effective amount of a salt of any one of claims 1 to 5~~.

48. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating inflammation in a patient ~~comprising~~ topical~~ly~~ administration~~administering to said patient a therapeutically effective amount of a salt of any one of claims 1 to 5~~.

49. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for~~A method of~~ treating rheumatoid arthritis in a patient ~~comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

50. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating prostate cancer ~~in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

51. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for~~A method of~~ treating psoriasis ~~in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

52. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating multiple myeloma in a patient ~~comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

53. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating myeloid metaplasia with myelofibrosis (MMM) in a patient ~~comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

54. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for~~A method of~~ treating polycythemia vera (PV) in a ~~patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

55. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for~~A method of~~ treating essential thrombocythemia (ET) in a patient ~~comprising administering to said patient a~~

~~therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

56. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for~~A method of~~ treating mycosis fungoides in a patient~~ comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

57. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating a hematological cancer in a patient~~ comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

58. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating chronic myelogenous leukemia (CML) in a patient~~ comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

59. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating acute lymphoblastic leukemia (ALL) in a patient~~ comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.

60. Use of a salt of any one of claims 1 to 5 in the preparation of a medicament for ~~A method of~~ treating chronic myelomonocytic leukemia (CMML) in a patient ~~comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 5, or pharmaceutically acceptable salt thereof~~.